ClinicalTrials.gg
Enrolling by invitationNCT07427927PROCTO-CLUSTERUpdated Aug 27, 2026

Data-driven Clustering in Hemorrhoid Surgery: Retrospective Monocentric Study for the Identification of Clinical Phenotypes

An observational study in Hemorrhoid and Hemorrhoid Prolapse, sponsored by IRCCS Policlinico S. Donato. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by IRCCS Policlinico S. Donato · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This retrospective, single-center observational study will use routinely collected perioperative data from adults undergoing surgery for symptomatic hemorrhoidal disease to identify data-driven clinical phenotypes. Unsupervised machine learning will be applied to characterize clusters of patients based on demographic, clinical, anatomical, and surgical variables. The study will explore whether the resulting phenotypes differ in operative complexity and postoperative course, and will generate hypotheses to inform future predictive models and personalized surgical planning.

Read the detailed description

Hemorrhoidal disease presents with heterogeneous symptom patterns, anatomical findings, and operative strategies that are not fully captured by traditional degree-based classifications. This study aims to identify latent, clinically interpretable phenotypes among surgical patients using a fully unsupervised machine learning pipeline applied to routinely collected perioperative data from a high-volume tertiary referral center.

This is a retrospective, observational analysis of de-identified institutional records. The analytic dataset will include routinely documented variables spanning baseline demographics/anthropometrics, symptom profile and relevant clinical history, operative technique and intraoperative descriptors, and routinely captured postoperative follow-up information. Data will be extracted using a predefined data dictionary and standardized preprocessing rules to support reproducibility and reduce variability in variable definitions.

The primary analytic approach will be unsupervised clustering. Variables will be cleaned and standardized prior to modeling. Dimensionality reduction will be performed using t-distributed stochastic neighbor embedding (t-SNE), initialized with principal component analysis to improve stability. Cluster discovery will then be conducted using k-means clustering on the reduced feature space. A range of cluster solutions will be explored, and the final solution will be selected using internal validity metrics (e.g., silhouette-based measures) together with assessment of clinical interpretability. Model robustness will be evaluated through repeated runs across multiple random seeds and key parameter settings to assess stability of cluster assignments.

After cluster assignment, clusters will be characterized using descriptive and comparative statistics to identify variables that most differentiate phenotypes. Post-hoc feature relevance/importance approaches will be used to explore which demographic, clinical, and surgical factors most strongly contribute to cluster formation, with emphasis on effect sizes and clinically meaningful patterns rather than hypothesis-testing alone. Findings will be used to generate hypotheses regarding phenotypes that may be associated with greater operative complexity and different postoperative trajectories, supporting future work on predictive modeling and individualized surgical decision support.

All analyses will be conducted within a controlled institutional environment using validated statistical and data-mining software, with documented parameter settings and version tracking to enable reproducibility. Only de-identified data will be used for analysis, and results will be reported in aggregate to protect patient privacy.

02

Conditions studied

  • Hemorrhoid
  • Hemorrhoid Prolapse

Browse trials for

Keywords

  • Hemorrhoidal Disease
  • Unsupervised Machine Learning
03

In context

Hemorrhoids

238 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

This study's planned enrollment of 100 is below the median of 151 across 49 observational studies indexed under Hemorrhoids.

Browse Hemorrhoids studies →

Lead sponsor

IRCCS Policlinico S. Donato is the lead sponsor of 103 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing surgery for symptomatic hemorrhoidal disease

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years
  • Clinical and/or intraoperative diagnosis of symptomatic hemorrhoidal disease
  • Availability of complete perioperative data: demographic, clinical, surgical, and postoperative variables Exclusion criteria
  • Incomplete or missing clinical data
  • Presence of anorectal neoplastic conditions (e.g., anal or rectal carcinoma)
  • Anorectal surgery within the previous 6 months (to avoid confounding effects on symptoms and anatomy)
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients who underwent surgery for symptomatic hemorrhoidal disease

    Consecutive patients who underwent surgery for symptomatic hemorrhoidal disease at IRCCS Policlinico San Donato between December 2024 and June 2025. Consecutive enrollment was chosen to minimize selection bias and to represent the full spectrum of disease severity in the surgical setting. Inclusion criteria Age ≥ 18 years Clinical and/or intraoperative diagnosis of symptomatic hemorrhoidal disease Availability of complete perioperative data: demographic, clinical, surgical, and postoperative variables Exclusion criteria Incomplete or missing clinical data Presence of anorectal neoplastic conditions (e.g., anal or rectal carcinoma) Anorectal surgery within the previous 6 months (to avoid confounding effects on symptoms and anatomy)

    Procedure: Any surgical procedure for hemorrhoidal disease

Interventions

  • ProcedureAny surgical procedure for hemorrhoidal disease

    standard hemorrhoidectomy, advanced hemorrhoidectomy, prolapsectomy, Doppler-guided procedures, or combined techniques

06

What researchers measure

Primary outcomes

  1. Internal validity of the unsupervised clustering solution (silhouette coefficient)

    Silhouette coefficient of the final k-means clustering solution derived from t-SNE-reduced perioperative data. The silhouette coefficient will be used as the primary internal validity metric to quantify cluster cohesion and separation for the selected number of clusters.

    Time frame: From completion of dataset extraction/cleaning through completion of clustering analysis (retrospective analysis of surgeries performed December 2024 to June 2025)

Secondary outcomes

  1. Cluster stability and reproducibility across model runs

    Stability of cluster assignments across multiple random seeds and t-SNE parameter settings (including perplexity), summarized by reproducibility/consistency of membership and stability of internal validity metrics across runs.

    Time frame: From completion of dataset extraction/cleaning through completion of clustering robustness analyses (retrospective analysis of surgeries performed December 2024 to June 2025)

  2. Operative duration (proxy of operative complexity)

    Operative duration (minutes) recorded in the operative report/perioperative database; compared across identified phenotypes.

    Time frame: Intraoperative (day of surgery)

  3. Postoperative pain intensity

    Pain intensity as documented in routine postoperative records/follow-up notes (e.g., numeric rating scale when available or clinician-documented pain status), analyzed as pain trajectory/pattern across early and intermediate follow-up and compared across clusters.

    Time frame: From surgery to 6 month postoperatively

  4. Postoperative complications (Clavien-Dindo classification)

    Any postoperative complication recorded in routine follow-up, graded according to the Clavien-Dindo system; complication rates and severity compared across clusters.

    Time frame: From surgery to 1 month postoperatively (early complications) and up to 6 months postoperatively (late complications)

  5. Time to return to routine activities

    Time to return to routine activities/work when documented in follow-up notes; compared across phenotypes.

    Time frame: From surgery to 1 month postoperatively

  6. Recurrence

    Recurrence patterns or persistence/return of hemorrhoid-related symptoms (e.g., bleeding/prolapse/other symptoms) as documented in routine follow-up and need for re-evaluation or additional intervention; compared across clusters.

    Time frame: 1 month and 6 months postoperatively

Other outcomes

  1. Cluster separation metrics (beyond silhouette)

    Additional internal cluster separation metrics (e.g., measures of between-cluster separation/within-cluster dispersion as implemented in the analytic workflow) reported to support interpretability of the phenotype solution.

    Time frame: From completion of dataset extraction/cleaning through completion of clustering analysis (retrospective analysis of surgeries performed December 2024 to June 2025)

  2. Between-cluster differences in clinical/anatomical/surgical characteristics

    Differences across clusters in routinely collected demographic and clinical history variables (e.g., age, sex, BMI, comorbidity burden, medications, symptom profile, bowel habit characteristics), anatomical descriptors (when documented), and procedure type/technique selection.

    Time frame: Baseline (preoperative assessment) and intraoperative (day of surgery)

  3. Post-hoc feature relevance for cluster formation

    Relative contribution/importance of demographic, clinical, and surgical variables to cluster formation assessed using post-hoc feature relevance approaches; used to interpret drivers of phenotype structure.

    Time frame: From completion of dataset extraction/cleaning through completion of post-hoc feature relevance analyses (retrospective analysis of surgeries performed December 2024 to June 2025)

07

Study locations

1 site
08

References and documents

Publications

  • Bernabe-Diaz JA, Franco M, Vivo JM, Fernandez-Breis JT. Optimizing clustering-based analytical methods with trimmed and sparse clustering. Comput Biol Med. 2025 Aug;194:110436. doi: 10.1016/j.compbiomed.2025.110436. Epub 2025 Jun 16. PubMed 40527163 ↗
  • Xiao C, Hong S, Huang W. Optimizing graph layout by t-SNE perplexity estimation. Int J Data Sci Anal. 2023;15(2):159-171. doi:10.1007/s41060-022-00348-7
  • Goldenholz DM, Sun H, Ganglberger W, Westover MB. Sample Size Analysis for Machine Learning Clinical Validation Studies. Biomedicines. 2023 Feb 23;11(3):685. doi: 10.3390/biomedicines11030685. PubMed 36979665 ↗
  • De Marco S, Tiso D. Lifestyle and Risk Factors in Hemorrhoidal Disease. Front Surg. 2021 Aug 18;8:729166. doi: 10.3389/fsurg.2021.729166. eCollection 2021. PubMed 34485376 ↗
  • Robinson PN, Mungall CJ, Haendel M. Capturing phenotypes for precision medicine. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000372. doi: 10.1101/mcs.a000372. PubMed 27148566 ↗
  • Brillantino A, Renzi A, Talento P, Brusciano L, Marano L, Grillo M, Maglio MN, Foroni F, Palumbo A, Sotelo MLS, Vicenzo L, Lanza M, Frezza G, Antropoli M, Gambardella C, Monaco L, Ferrante I, Izzo D, Giordano A, Pinto M, Fantini C, Gasparrini M, Schiano Di Visconte M, Milazzo F, Ferreri G, Braini A, Cocozza U, Pezzatini M, Gianfreda V, Di Leo A, Landolfi V, Favetta U, Agradi S, Marino G, Varriale M, Mongardini M, Pagano CEFA, Contul RB, Gallese N, Ucchino G, D'Ambra M, Rizzato R, Sarzo G, Masci B, Da Pozzo F, Ascanelli S, Liguori P, Pezzolla A, Iacobellis F, Boriani E, Cudazzo E, Babic F, Geremia C, Bussotti A, Cicconi M, Sarno AD, Mongardini FM, Brescia A, Lenisa L, Mistrangelo M, Zuin M, Mozzon M, Chiriatti AP, Bottino V, Ferronetti A, Rispoli C, Carbone L, Calabro G, Tirro A, de Vito D, Ioia G, Lamanna GL, Asciore L, Greco E, Bianchi P, D'Oriano G, Stazi A, Antonacci N, Renzo RMD, Poto GE, Ferulano GP, Longo A, Docimo L. The Italian Unitary Society of Colon-Proctology (Societa Italiana Unitaria di Colonproctologia) guidelines for the management of acute and chronic hemorrhoidal disease. Ann Coloproctol. 2024 Aug;40(4):287-320. doi: 10.3393/ac.2023.00871.0124. Epub 2024 Aug 30. PubMed 39228195 ↗
  • De Gregorio MA, Guirola JA, Serrano-Casorran C, Urbano J, Gutierrez C, Gregorio A, Sierre S, Ciampi-Dopazo JJ, Bernal R, Gil I, De Blas I, Sanchez-Ballestin M, Millera A. Catheter-directed hemorrhoidal embolization for rectal bleeding due to hemorrhoids (Goligher grade I-III): prospective outcomes from a Spanish emborrhoid registry. Eur Radiol. 2023 Dec;33(12):8754-8763. doi: 10.1007/s00330-023-09923-3. Epub 2023 Jul 17. PubMed 37458757 ↗
  • van Oostendorp JY, Grossi U, Hoxhaj I, Kimman ML, Kuiper SZ, Breukink SO, Han-Geurts IJM, Gallo G. Limitations of the Goligher classification in randomized trials for hemorrhoidal disease: a qualitative systematic review of selection criteria. Tech Coloproctol. 2025 Jun 10;29(1):133. doi: 10.1007/s10151-025-03170-y. PubMed 40493094 ↗
  • Dekker L, Han-Geurts IJM, Grossi U, Gallo G, Veldkamp R. Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease? Tech Coloproctol. 2022 May;26(5):387-392. doi: 10.1007/s10151-022-02591-3. Epub 2022 Feb 9. PubMed 35141793 ↗
  • Bozovic B, Radoicic M, Jankovic S, Andelkovic J, Kostic M. Pharmacoeconomic Aspects of Treating Hemorrhoidal Disease-Cost of Illness Study Based on Data from Balkan Country with Recent History of Social and Economic Transition. Iran J Public Health. 2021 Jun;50(6):1288-1290. doi: 10.18502/ijph.v50i6.6433. No abstract available. PubMed 34540753 ↗
  • Rorvik HD, Davidsen M, Gierloff MC, Brandstrup B, Olaison G. Quality of life in patients with hemorrhoidal disease. Surg Open Sci. 2023 Feb 24;12:22-28. doi: 10.1016/j.sopen.2023.02.004. eCollection 2023 Mar. PubMed 36876020 ↗
  • Pata F, Gallo G, Pellino G, Vigorita V, Podda M, Di Saverio S, D'Ambrosio G, Sammarco G. Evolution of Surgical Management of Hemorrhoidal Disease: An Historical Overview. Front Surg. 2021 Aug 30;8:727059. doi: 10.3389/fsurg.2021.727059. eCollection 2021. PubMed 34527700 ↗
  • Roberts K. What Are Hemorrhoids? JAMA. 2025 Nov 6. doi: 10.1001/jama.2025.17253. Online ahead of print. PubMed 41196608 ↗
  • Wang L, Ni J, Hou C, Wu D, Sun L, Jiang Q, Cai Z, Fan W. Time to change? Present and prospects of hemorrhoidal classification. Front Med (Lausanne). 2023 Oct 11;10:1252468. doi: 10.3389/fmed.2023.1252468. eCollection 2023. PubMed 37901411 ↗
  • Al-Masoudi RO, Shosho R, Alquhra D, Alzahrani M, Hemdi M, Alshareef L. Prevalence of Hemorrhoids and the Associated Risk Factors Among the General Adult Population in Makkah, Saudi Arabia. Cureus. 2024 Jan 3;16(1):e51612. doi: 10.7759/cureus.51612. eCollection 2024 Jan. PubMed 38318578 ↗
  • Error in Figure 4 and References. JAMA. 2025 Oct 7;334(13):1203. doi: 10.1001/jama.2025.17752. No abstract available. PubMed 40952854 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Dec 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 23, 2026
StartActual
Dec 1, 2024
Primary completionActual
Dec 31, 2025
CompletionEst.
Dec 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07427927
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Dec 1, 2024
Primary completion
Dec 31, 2025
Completion
Dec 2026 (estimated)
Last update
Aug 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion